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Abstract: Parkinson’s disease (PD) is a progressive neurodegenerative disease affecting  
the nigrostriatal pathway, where patients do not manifest motor symptoms until >50% of 
neurons are lost. Thus, it is of great importance to determine early neuronal changes that 
may contribute to disease progression. Recent attention has focused on lipids and their role 
in pro- and anti-apoptotic processes. However, information regarding the lipid alterations  
in animal models of PD is lacking. In this study, we utilized high performance liquid 
chromatography electrospray ionization tandem mass spectrometry (HPLC-ESI-MS/MS) 
and novel HPLC solvent methodology to profile phosphatidylcholines and sphingolipids 
within the substantia nigra. The ipsilateral substantia nigra pars compacta was collected  
from rats 21 days after an infusion of 6-hydroxydopamine (6-OHDA), or vehicle into the 
anterior dorsal striatum. We identified 115 lipid species from their mass/charge ratio using 
the LMAPS Lipid MS Predict Database. Of these, 19 lipid species (from phosphatidylcholine 
and lysophosphotidylcholine lipid classes) were significantly altered by 6-OHDA, with most 
being down-regulated. The two lipid species that were up-regulated were LPC (16:0) and 
LPC (18:1), which are important for neuroinflammatory signalling. These findings provide 
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a first step in the characterization of lipid changes in early stages of PD-like pathology and 
could provide novel targets for early interventions in PD. 
Keywords: lipidomic profile; Parkinson’s disease; early stage model; 6-hydroxydopamine; 
HPLC-ESI-MS/MS 
 
1. Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disease which affects the dopaminergic 
nigrostriatal pathway, a brain region critical in the initiation and control of motor behaviour. The 
degeneration, which occurs over many decades [1] eventually causes severe motor and cognitive  
deficits [2–4]. The primary symptoms of PD are muscle tremors and rigidity within the distal limbs, 
bradykinesia (slowed movements), and general gait disturbances. Typically PD patients do not begin to 
manifest primary symptoms until 50%–80% of the nigrostriatum has degenerated [1], resulting in 
delayed treatments and an overall poorer prognosis. Therefore, identifying early neuronal changes which 
characterize the early phase of PD (early stage of disease that precedes the manifestation of full blown 
primary symptoms) is of great importance. Indeed, identifying biomarkers that could help classify the 
trajectory of illness in PD would greatly aid in the treatment process, as well as provide potential novel 
targets for the development of future therapeutics. 
We have recently utilized a low dose of the specific neurotoxin 6-hydroxydopamine (6-OHDA) to 
induce a prodromal-like PD state. Specifically, an infusion of 6-OHDA into the dorsal striatum resulted 
in a modest partial lesion which encompassed 10% and 15% of the striatal volume at two and four weeks 
after toxin administration, respectively [5]. We also found that our model resulted in no difference in the 
number of neurons within the substantia nigra (SNc); however, as would be expected in the early stages 
of PD, many of the neurons had morphology typically seen in unhealthy cells, specifically increased 
vacuolization, decreased dendritic projections, and an overall decreased cell volume [5]. Additionally, 
numerous other reports have indicated that pro-death oxidative and mitochondrial stress pathways are 
likely involved in the early stages of PD, and that pro-inflammatory factors also arise to contribute to 
primary or secondary pathological processes active in the disease [6–8]. At the same time, certain genetic 
mutations (e.g., LRRK2, Parkin, PINK1) can lead to a familial form of PD or increase the vulnerability 
to a host of environmental insults, such as pesticides and heavy metals [9,10]. Surprisingly however, 
scant evidence exists regarding the potential importance of lipid alterations in PD. This is particularly 
surprising given that many of the toxicants implicated in PD are highly lipid soluble and in fact, 
accumulate to a substantial degree in brain lipid membranes [11]. 
Recent attention has focused on lipids and their role in both cell-signalling pathways that govern 
survival or neurodegeneration. Lysophosphotidylcholines (lysoPC), for example, have been associated 
with pro-apoptotic processes by activating various deleterious signalling cascades, such as activation of 
the Bid BH3 protein and caspase-3 [12]. LysoPC species have also been shown to cause decreased 
expression of the anti-apoptotic TNF receptor-associated factor (TRAF) 2 [13]. Comparatively, 
sphingolipids (SP) have an interesting dichotomous effect, such that they can act as both a pro-apoptotic 
and anti-apoptotic second messenger, wherein the difference between the two signalling pathways 
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appears to be dependent on the site of lipid cleavage [14]. Both SP and lysoPC lipid species are derived 
from phosphatidylcholines (PC), a lipid class which is an important mediator in various structural and 
signalling roles, having previously been implicated in numerous processes, such as cellular growth and 
survival [15]. Yet, in many cases it is still unclear as to whether the effects are due to direct signalling 
by the lipids themselves as second messengers, or due to hyper- or hypoactivity of their associated 
enzymes [14,15]. 
In the present investigation, we analyzed the lipid profiles evident in the substantia nigra region of 
rats subjected to our 6-OHDA early stage model of PD. We then compared the relative quantity and 
structure of PC, lysoPC and SP using HPLC-ESI-MS/MS. Importantly, we employed a novel HPLC 
solvent methodology to separate and identify the different lipids according to their individual mass to 
charge (m/z) ratio. It is our belief that this broad lipidomics profile can be used as a starting point to 
investigate the role of lipidomic signaling in the etiology and progression of PD, as well as to further 
expand research directed at identifying detectable biomarkers of the neurodegenerative condition. 
2. Results and Discussion 
2.1. Results 
Our lipidomics profile scan identified 115 different lipid species, of these, 19 (16.5%) were 
significantly changed in the 6-OHDA treated animals. We found that 17 (89.5%) of these significantly 
altered lipids were down-regulated and only 2 (10.5%) were up-regulated. PC species were primarily 
affected accounting for 63.2% of all significantly altered lipids (12/19), and were found to be entirely 
down-regulated (Figure 1). Similarly, we found that lysoPC species were mainly down-regulated  
(Figure 2); however two notable lysoPC lipids were up-regulated; LPC (16:0) and LPC (18:1). The two 
upregulated lysoPC lipids were also found to be in the highest relative concentrations, with normalized 
peak area values in the 6-OHDA treated animals being 379 and 294 for LPC (16:0) and (18:1) 
respectively. Comparatively, the average normalized peak area for all other lysoPC lipids is 1.84, and 
1.90 for PC lipids. Finally, we found that 36.8% of the significantly altered lipids contained  
ether-linked acyl chains. A summary of our findings can be found in Table 1. 
Table 1. Summary table of lipidomic findings. The class of lipids was determined using the 
LIPID MAPS MS Prediction Tool. 
Category n 
Lipids Identified 115 
Lipids with Significant Changes 19 
Lipids up-regulated in 6-OHDA Animals 2 
Lipids down-regulated in 6-OHDA Animals 17 
Phosphatidylcholines with Significant Changes 12 
Lysophosphatidylcholines with Significant Changes 7 
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Figure 1. The relative abundance of phosphatidylcholine species in the substantia nigra of 
animals treated with either 6-OHDA (20 µg) or saline vehicle into the right anterior dorsal 
striatum, as determined by HPLC-ESI-MS/MS measurements. All measurements were run 
in triplicate and the error bars represent the standard error. Only species displaying 
significant differences between treatment and control groups are shown. Significance was 
determined by independent sample t-test. The relative fold change of phosphatidylcholine 
species is represented along the X-axis in the form of a color heat map. 
 
Figure 2. The relative abundance of lysophosphotidylcholine species in the substantia nigra 
of animals treated with either 6-OHDA (20 µg) or saline vehicle into the right anterior dorsal 
striatum, as determined by HPLC-ESI-MS/MS measurements. All measurements were run 
in triplicate and the error bars represent the standard error. Only species that were 
significantly differences between treatment and control groups are shown. Significance was 
determined by independent sample t-test. The relative fold change of lysophosphotidylcholine 
species is represented along the X-axis in the form of a color heat map. 
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2.2. Discussion 
In this study we used a relatively low dose of 6-OHDA to induce a partial nigrostriatal lesion, which 
we believe may partially model a prodromal-like PD state. We have recently found that this animal 
model causes modest striatal lesions, coupled with morphological abnormalities of surviving  
neurons [5]. In the present study, we found that PC lipid species were markedly altered in animals treated 
with 6-OHDA. By far, PC species were the most affected and were generally down-regulated in all cases. 
Importantly, PC lipids are major components of many cell structures [15], including being present with 
exceptionally high levels in vacuole membranes [16]. The possibility exists that the decrease of PC lipids 
in 6-OHDA treated mice reflects some degree of structural rearrangement. In effect, as neurons develop 
PD like pathology (e.g., decreased dendritic projections, decreased cell volume and cell death) the cell 
may simply require significantly lower PC lipid concentrations. 
In addition to structural support, PC lipids may also contribute to functional aspects of neuronal 
processes by influencing various signalling pathways. For instance, previous studies have reported that 
PC lipids modulate anti-inflammatory signaling [17]. Moreover, it is known that 6-OHDA can induce 
microglial reactivity [5,18,19] and elevations of pro-inflammatory cytokines [20–22]. Thus, the decrease 
in PC lipids currently observed may influence cell survival in the context of 6-OHAD treatment by 
influencing inflammatory processes. 
Although 6-OHDA can provoke pro-apoptotic effects through the protein kinase Cδ (PKCδ) complex 
system [23], this same system can also impart anti-apoptotic consequences through diacylglycerol 
(DAG) molecules, which are primary PC lipid metabolites [24,25]. This raises the possibility that the 
array of lipids modulated by 6-OHDA are likely engaged in a sort of cellular “tug of war” concerning 
neuronal survival pathways. Another potential source of anti-apoptotic DAG is via sphingomyelin 
synthase, an enzyme that combines a ceramide and PC lipid to cause the synthesis of a SP and DAG 
molecule [15]. Although our findings did not show any significant changes in SP lipids, we did find 
trends in which up-regulations of sphingosine and sphinganine approached significance. 
Similar to our PC results, we found an overall decrease in lysoPC species among 6-OHDA treated 
animals. However, there were two notable exceptions, such that LPC (16:0) and (18:1) were greatly 
increased in 6-OHDA treated animals. LysoPC are lipids synthesized from PCs via the enzyme 
phospholipase A2 (PLA2). 6-OHDA has been reported to induce PLA2 enzymatic activity within the 
nigrostriatal tract [26,27]. Interestingly, increased PLA2 activity has been repeatedly associated with 
apoptotic effects [28,29] including 6-OHDA induced apoptosis [30]. However the role of PLA2 is 
exceedingly complex, as the enzyme has also been implicated in anti-apoptotic pathways, primarily via 
the arachidonic acid and peroxisome proliferator-activated receptor (PPAR) signalling pathway [31]. 
Arachidonic acid and PPAR system activation has also been shown to reduce oxidative stress and 
normalize mitochondrial dysfunction [31,32]; both of which are affected by 6-OHDA [33–36]. 
Interestingly, both LPC (16:0) and LPC (18:1) have been shown to play major roles in regulating PLA2 
enzyme activity by acting as an uncompetitive inhibitor [37]. Alternatively, the accumulation of these 
LPC species could be related to impairment of other enzymes in the PC re-acylation or de-acylation 
processes. However, as the literature is lacking on the role of these other enzymes in PD and PD-like 
pathology, with further enzymology follow up studies required. 
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It is also possible that the observed increase in LysoPC species (16:0) and (18:1) is unrelated to altered 
6-OHDA induced PLA2 enzymatic activity, and instead could be increased to serve a very specific and 
targeted role by acting as immune signalling mediators. In this regard, it has been shown that LysoPC 
(16:0) and (18:1) play a major role in inflammatory signaling [37], including the release of various 
cytokines (interlukin-1β, interlukin-6, chemokine ligand 2, chemokine ligand 4, and tumor necrosis 
factor alpha) [38,39]. Importantly, the two LPC species have also have potent chemotactic abilities, being 
able to induce and recruit macrophages and T-lymphocytes to injured tissue [38,40–42]. Given these 
findings, it is possible that the overall decrease of lysoPC species, as a class of lipids, is related to changes 
in PLA2 activity, whereas, the dramatic increase in LysoPC (16:0) and (18:1) may arise from their 
involvement in inflammatory processes induced by 6-OHDA. Finally, it is important to point out that 
we currently report relative differences between the various species rather than absolute lipid levels. 
Indeed, we are most interested in lipid profile changes that might be characteristic of early stages PD. 
In addition to “typical” PC and lysoPC species, we identified numerous “atypical” ether linked forms 
of these species; all of which were down-regulated. In agreement with our current findings, it has also 
been reported that PD patients had significantly decreased levels of ether-linked lipids [43]. Ether linked 
lipids are known to generally be platelet activating factors, and have been shown to be heavily involved 
in the neuroinflammatory responses [44]. Importantly, drugs that antagonize ether-linked phospholipids 
have potential clinical relevance given their reported neuroprotective and anti-tumorigenic effects [45,46]. 
It is of considerable importance to underscore that we currently assessed lipid levels in the SNc, which 
normally sends projections “downstream” to the striatum to modulate basal ganglia activity. Thus, the 
observed lipid changes are presumably upstream from the neurotoxin-injected striatum, indicating that 
they likely stem from retrograde signalling pathways. Indeed, the view is widely held that PD begins 
with a loss of function and degeneration of the axon terminals in the striatum, which then progresses 
back to the cell bodies in the SNc [47–50]. Further to this point, the intra-striatal 6-OHDA model of PD 
is also known to induce progressive neuronal degeneration over numerous weeks [51,52] and causes 
increased neuroinflammatory responses [20,22,53]. Additionally, we used a low dose of 6-OHDA which 
we have recently reported to cause a modest but significant loss of dopamine (DA) striatal terminals, but 
does not significantly affect the number of neurons within SNc [5]. Taken together, these findings 
suggest that the intra-striatal 6-OHDA model of PD can be an important tool for the investigation of the 
early stages of PD as it mimics the human condition in many key aspects. 
Mitochondrial dysfunction is an important contributor to PD pathology, and indeed 6-OHDA acts 
primarily via disruption of mitochondrial processes, resulting in the generation of reactive oxygen 
species [33,54]. It is important to note, however, that our assay results in the extraction of general cellular 
and not specific mitochondrial lipids per se. Methods to isolate mitochondrial lipids in a manner that 
renders them amenable to MS analysis are difficult to perform and introduce a great deal of variability. 
In the current study, we can only identify the general structure of the various lipid species. Identifying 
the full fatty acid composition can be achieved with further MS2 analysis using either lithium or acetate 
adduction methods. However, these methods pose significant limitations, as they are effective for 
standards, but can be problematic when using complex tissue samples (as they become difficult to 
separate chromatographically). Both adduction methods are also substantially less sensitive than those 
involving the production of protonated phosphocholine fragment ions, such as the precursor m/z 184 
scan in positive ion mode (as outlined in the detailed methods section) was used in the current study. 
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Besides identifying novel lipids that could be mechanistically involved in PD, the present findings 
could conceivably have implications for the development of biomarkers. Of course, for a molecule to be 
a useful biomarker it must be readily detectable in peripheral tissue and/or fluids. In this regard, a recent 
study detected increases in 9 ceramide class lipids in the plasma of PD patients [55]. Moreover, several 
PC and lysoPC lipid alterations were found in the plasma of patients with Alzheimer’s disease [56]. 
Future studies are required to assess whether 6-OHDA induces peripheral lipid changes that parallel the 
presently observed brain lipid changes. However, current evidence is promising and the use of lipidomics 
screens as a potential tool for early diagnosis of PD may play an important role in the future. 
3. Experimental Section 
3.1. Animals 
Six male Sprague Dawley rats (Charles River), weighing between 250–280 g on arrival were used  
in the current experiments. The animals were individually housed in a standard polypropylene cage  
(27 × 48 × 20 cm) and maintained a 12-h light/dark cycle. Tap water and food (Harlan Rat Chow, 
Somerville, NJ, USA) was provided ad libitum, while room temperature and humidity were maintained 
at 20 °C and 50%, respectively. All aspects of this experiment were approved by the Carleton University 
Committee for Animal Care (P10-28, 3 January 2013) and adhered to the guidelines outlined by the 
Canadian Council for the Use and Care of Animals in Research. 
3.2. Surgery 
The animals were anaesthetized using variable flow isoflurane inhalational anesthetic (isoflurane 
volume of 2%–3% in pure O2). Animals were then placed in a Kopf instruments Model 940 stereotaxic 
frame (Kopf Instruments, Tujunga, CA, USA) with the incisor bar positioned 3.3 mm below the incisor 
line. An L-shaped PlasticsOne 328OP Osmotic Pump Cannula was implanted in the right striatum at  
the coordinates 1.0 mm anterior, 3.0 mm lateral and 5.0 mm ventral relative to bregma and skull surface. 
A single infusion of 20 μg of 6-hydroxydopamine (Sigma, St. Louis, MO, USA; purchased as a 
hydrochloride salt, n = 3) in 0.9% injectable saline (containing 0.02% ascorbic acid), or vehicle solution 
(n = 3), was given at a rate of 1 μL/min using a Hamilton 25 μL syringe with a 22 gauge needle attached 
to a Harvard Apparatus PicoPlus 11 Pump (Harvard Apparatus, Holliston, MA, USA). The vehicle 
solution was made fresh daily and the 6-hydroxydopamine hydrochloride salt was mixed immediately 
before the infusion. After the infusion the cannula remained in place for an additional 5 min before  
being removed to ensure maximal diffusion of the 6-hydroxydopamine solution. BoneWax® (Stoelting,  
Wood Dale, IL, USA) was placed over the drill hole in the skull and the incision site was clipped using 
EZclip® surgical staples (Stoelting, Wood Dale, IL, USA). A single application of 2% lidocaine 
hydrochloride topical anaesthetic jelly (Xylocaine, AstraZeneca, CDMV, Saint-Hyacinthe, QC, Canada) 
was applied to the incision site. 
3.3. Euthanasia 
Animals were deeply anesthetized with an injection of sodium pentobarbital and subsequently 
euthanized via transcardial perfusion using a chilled 0.9% saline solution 21 days after the surgical 
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infusion. The ipsilateral substantia nigra (SNc) was isolated from the extracted brain by dissecting the 
appropriate coronal section using a Kopf Instruments rat blocker obtaining a 2 mm slice approximately 
−4.3 to −6.3 mm with respect to bregma using the Paxinos and Watson rat atlas [57]. The coronal slice 
was then further dissected manually using a clean razor blade so as to isolate only the region of tissue 
containing the substantia nigra. The extracted tissue was immediately flash frozen using 100% ethanol 
on dry ice. All samples were stored at −80 °C until ready for lipid extraction. 
3.4. Lipid Extraction 
All samples were individually weighed using an analytical balance, measured in grams and accurate 
to 5 decimal places, to be used later in the data analysis. The extracted tissue was then homogenized via 
sonication in a solution containing 3.2 mL 0.1 M sodium acetate, 4 mL acidified methanol (2% acetic 
acid), and 41.3 µL of 10 µM C13:0 LPC (internal standard). Lipids where extracted via liquid–liquid 
extraction using 3.8 mL of chloroform, centrifuged at 3000 RPM for 2 min at 4 °C. Chloroform 
extraction was repeated 3 more times using 2 mL chloroform, each replicate being centrifuged at  
2000 RPM for 2 min at 4 °C to ensure extraction of all lipids from the original homogenate solution. 
The extracted chloroform layers were evaporated using ultrapure nitrogen gas, and lipids were 
subsequently re-suspended in 300 µL absolute ethanol. Lipid samples were stored at −20 °C, and were 
analyzed via HPLC-ESI-MS/MS within 48 h of being extracted. 
3.5. HPLC-ESI-MS/MS 
Fifteen centimeter lengths of 200 μm inner diameter fused silica (PolymicroTechnologies, Phoenix, 
AZ, USA) were dipped in a 3:1 solution of Kasil 1678 potassium silicate and formamide (Promega, 
Madison, WI, USA) to make a column frit on one end. The columns were allowed to dry for 24 h, were 
shortened to 10 cm, and subsequently packed with 5 cm of 5 μm ReproSil-Pur C4 stationary phase beads 
(Dr. Maisch GmbH, Ammerbuch, Germany) in acetone using a nitrogen pressure vessel. A PicoFrit 
Emitter (New Objective, Woburn, MA, USA) was filled in a similar manner, however only 1 cm of 
ReproSil-Pur C4 beads were used. 
Test samples were prepared immediately before each run (1 μL of concentrated lipid sample, 5 μL  
of absolute ethanol, and 34 μL of deionized water). Samples were placed into a Dionex UltiMate  
3000 autosampler (Thermo Fisher Scientific, Waltham, MA, USA) maintained at 4 °C and loaded  
onto the chromatography column using a Dionex UltiMate 3000 pump (Thermo Fisher Scientific, 
Waltham, MA, USA, 20 µL total volume). All mobile phases were prepared using HPLC grade solvents: 
(A) 30% methanol in 10 mM ammonium acetate; (B) isopropanol with 10 mM ammonium acetate and 
(C) hexane. Each lipid mass analysis was 60 min in length and began with a 100% A mobile phase.  
Four min later solvent B was gradually increased until the mobile phase became 100% B at the 45.5 min 
mark where is remained at 100% B for 1 min. At the 46.6 min mark solvent C gradually increased until 
the mobile phase became 100% C where it remained until the end of the run. 
Chromatographically separated lipids were directly analyzed using an AB Sciex 4000 QTRAP  
ESI-MS/MS Hybrid Triple Quadrupole/Linear Ion Trap (AB Sciex, Framingham, MA, USA). The 
QTRAP was run in positive ion mode, with the ESI nanospray voltage set at 3 kV, curtain gas at 20 and 
declustering potential at 25 V. A precursor ion scan and an enhanced mass spectrum (EMS) were 
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conducted using a mass range of 250–1500 Da. The precursor ion scan was set to analyze precursors of 
m/z 184 with a collision energy of 40.0 eV and collision cell exit potential of 10 V. 
Immediately after each lipid sample was analyzed, a 140 min hexane wash was run (90% C and  
10% B). Towards the end of the wash at the 130 min mark the mobile phase switched to 100% B and 
before switching to 100% A at 137 min. A 40 min blank was run immediately following the wash cycle 
to ensure there was no carry over. The mobile phase began with 100% A before gradually switching to 
100% B at starting a 4 min and ending at 28 min. The mobile phase remained at 100% B for another 
minute before returning to 100% A until the end of the run. All samples were run in triplicate. 
3.6. Data Analysis 
Mass spectra were analyzed using Analyst Software version 1.5.1 (AB Sciex, Concord, ON, Canada). 
The precursor m/z 184 scan was manually analyzed to generate a list of phosphatidylcholine and 
sphingolipid m/z-values. The m/z-values (±0.2 Da) were then entered into MultiQuant 2.1.1 (AB Sciex, 
Concord, ON, Canada). All desired peaks were integrated and an output containing a variety of 
parameters, such as peak area and retention time, was generated. The peak area of each lipid was divided 
by the peak area of the internal standard C13:0 LPC (m/z 454), and then again by the total weight of the 
substantia nigra. The triplicate data was averaged for each animal providing a biological n of 3 per 
treatment group. LIPID MAPS MS Prediction Tool (LIPID MAPS, San Diego, CA, USA) was then used 
to determine the classification and to predict the structure of all lipid masses identified in the precursor 
m/z 184 scan. Statistical significance between treatment groups for each lipid species was determined 
using independent-samples t-tests. 
4. Conclusions 
We report that 21 days after an intrastriatal infusion of a low dose of 6-OHDA there are significant 
decreases in PC and lysoPC within the SNc. Two lipids, LysoPC (16:0) and (18:1) stood out in that they 
greatly upregulated by 6-OHDA. Although speculative, these observed lipid changes may contribute to 
structural reconfiguration, immune system signalling, and pro- and anti-apoptotic pathways. This broad 
lipidomic profile is novel and might be used to further investigate the role of specific lipid species in the 
etiology and progression of PD, as well as providing potential biomarkers for PD progression. Of course, 
to be ultimately useful in this capacity, future work will be required to determine whether peripheral 
lipid species change in parallel with the presently observed SNc variations. Finally, it is particularly 
noteworthy that the series of marked lipid changes occurred within the SNc, which is of course, up-stream 
of the 6-OHDA injected striatum. Thus, our findings clearly indicate that retrograde signals likely 
emanated from the partially lesioned striatum to modulate lipid composition within the SNc cell soma. 
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